The Latest Cardiac and Vascular News
FRANKLIN LAKES, N.J., June 1, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today appointed John A. DeFord as executive vice president and chief technology officer. DeFord, 56, will report to Tom Polen, president of BD, and will be responsible for leading […]
FRANKLIN LAKES, N.J., May 3, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.222 billion for the second fiscal quarter ended March 31, 2018. This represents an increase of 42.2 percent from the prior-year period, which is primarily due to the acquisition […]
FRANKLIN LAKES, N.J., April 23, 2018 /PRNewswire/ — The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.75 per common share, payable on June 29, 2018 to holders of record on June 8, 2018. The indicated annual dividend rate is $3.00 per share. In addition, the Board of Directors has declared […]
FRANKLIN LAKES, N.J., Feb. 15, 2018 /PRNewswire/ — Becton, Dickinson and Company (NYSE: BDX), a leading global medical technology company, announced today that it has completed the previously announced divestitures of its soft tissue core needle biopsy product line and Aspira® product line to Merit Medical Systems, Inc. following receipt of all required […]
FRANKLIN LAKES, N.J., Jan. 18, 2018 /PRNewswire/ — Becton, Dickinson and Company (NYSE: BDX), a leading global medical technology company, today announced the completion of enrollment in the Lutonix below-the-knee (BTK) trial and plans to submit a pre-market approval application in late 2018. The Lutonix BTK trial is a prospective, multicenter, randomized, […]
FRANKLIN LAKES, N.J., Dec. 22, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today’s clearance by the U.S. Federal Trade Commission (FTC) for BD to acquire C. R. Bard (NYSE: BCR), contingent on the divestitures of BD’s soft tissue core […]
FRANKLIN LAKES, N.J., Oct. 18, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today’s clearance by the European Commission for BD to acquire C.R. Bard (NYSE: BCR), contingent on BD divesting its soft tissue core needle biopsy product line: “We […]
VANCOUVER, British Columbia, May 16, 2017 /PRNewswire/ — According to a new series of reports on the Australia vascular access device market by iData Research (www.idataresearch.com), peripheral intravenous catheters (PIVCs) and dialysis catheters represent the fastest growing segments in the vascular access market in the region. The PIVC segment is growing […]
